Crystec’s Chief Scientist will be presenting during this year’s Making Pharmaceuticals conference in Coventry. Professor Peter York will speak about “In-Particle Formulation Design and Processing - the KISS Strategy” and will be available to discuss Crystec’s mSAS (modified Supercritical Anti-Solvent) technology at stand 234.
Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing. The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development, and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.
China Resources Pharmaceutical Group and CrystecPharma enter agreement to bridge research and innovation between China and the UK
Crystec’s Chief Scientist, Prof. Peter York, and China Resources Pharmaceutical’s President, Mr. Wang Chuncheng, were hosted by the UK Department of International Trade to sign a strategic cooperation agreement.
The partnership between Crystec and Juniper Pharma Services has reached another key milestone, with Crystec’s commercial scale supercritical fluid rig now on-site at Juniper Pharma Services in Nottingham.